What is AM(FDC) used for?

AM(FDC) is indicated for Epilepsy.

AM(FDC) is developed by Medecins Sans Frontieres, Netherlands.

What development phase is AM(FDC) in?

AM(FDC) is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

AM(FDC)

Medecins Sans Frontieres, Netherlands · FDA-approved active Small molecule Quality 10/100

At a glance

Generic name	AM(FDC)
Also known as	Far-Manguinhos, Brazil
Sponsor	Medecins Sans Frontieres, Netherlands
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	FDA-approved

Approved indications

Epilepsy

Common side effects

No common side effects on file.

Key clinical trials

Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Participants (PHASE1)
Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension (PHASE3)
Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AM(FDC) CI brief — competitive landscape report
AM(FDC) updates RSS · CI watch RSS
Medecins Sans Frontieres, Netherlands portfolio CI